PHAXIAM Therapeutics Future Growth
Future criteria checks 0/6
PHAXIAM Therapeutics's revenue and earnings are forecast to decline at 94% and 4.8% per annum respectively while EPS is expected to grow by 38.8% per annum.
Key information
-4.8%
Earnings growth rate
38.8%
EPS growth rate
Biotechs earnings growth | 21.1% |
Revenue growth rate | -94.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Feb 2024 |
Recent future growth updates
No updates
Recent updates
ERYTECH receives non-compliance letter from Nasdaq
Oct 13Erytech Pharma reports 1H results
Sep 12Erytech drops plans to pursue FDA approval for leukemia therapy
Aug 24Our First Look At ERYTECH Pharma
Nov 16ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation
May 06ERYTECH starts patient enrollment in pancreatic cancer study
Jan 14ERYTECH secures €10M in non-dilutive financing
Nov 02ERYTECH: Trials In Pancreatic Cancer
Oct 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -21 | -21 | N/A | 1 |
12/31/2025 | N/A | -21 | -21 | N/A | 1 |
12/31/2024 | N/A | -20 | -20 | N/A | 1 |
12/31/2023 | N/A | -26 | -27 | N/A | 1 |
9/30/2023 | 6 | -12 | N/A | N/A | N/A |
6/30/2023 | 6 | -11 | -23 | -23 | N/A |
3/31/2023 | 6 | 6 | N/A | N/A | N/A |
12/31/2022 | 7 | 0 | -32 | -32 | N/A |
9/30/2022 | 2 | -18 | N/A | N/A | N/A |
6/30/2022 | 3 | -27 | -45 | -45 | N/A |
3/31/2022 | 3 | -54 | N/A | N/A | N/A |
12/31/2021 | 4 | -54 | -57 | -57 | N/A |
9/30/2021 | 4 | -61 | N/A | N/A | N/A |
6/30/2021 | 4 | -66 | -55 | -55 | N/A |
3/31/2021 | 4 | -68 | N/A | N/A | N/A |
12/31/2020 | 4 | -73 | -53 | -52 | N/A |
9/30/2020 | 4 | -73 | N/A | N/A | N/A |
6/30/2020 | 4 | -68 | -52 | -49 | N/A |
3/31/2020 | 5 | -69 | N/A | N/A | N/A |
12/31/2019 | 5 | -63 | -63 | -43 | N/A |
9/30/2019 | 6 | -52 | -69 | -38 | N/A |
6/30/2019 | 5 | -49 | -73 | -52 | N/A |
3/31/2019 | 4 | -38 | N/A | N/A | N/A |
12/31/2018 | 4 | -38 | -53 | -48 | N/A |
9/30/2018 | 3 | -42 | N/A | N/A | N/A |
6/30/2018 | 4 | -38 | -33 | -31 | N/A |
3/31/2018 | 3 | -39 | N/A | N/A | N/A |
12/31/2017 | 3 | -34 | -26 | -25 | N/A |
9/30/2017 | 4 | -27 | N/A | N/A | N/A |
6/30/2017 | 4 | -26 | N/A | -23 | N/A |
3/31/2017 | 5 | -24 | N/A | N/A | N/A |
12/31/2016 | 4 | -22 | N/A | -18 | N/A |
9/30/2016 | 4 | -20 | N/A | -17 | N/A |
6/30/2016 | 4 | -19 | N/A | -17 | N/A |
3/31/2016 | 3 | -16 | N/A | N/A | N/A |
12/31/2015 | 3 | -15 | N/A | -15 | N/A |
9/30/2015 | 3 | -14 | N/A | -12 | N/A |
6/30/2015 | 2 | -12 | N/A | -10 | N/A |
3/31/2015 | 2 | -11 | N/A | -9 | N/A |
12/31/2014 | 2 | -9 | N/A | -7 | N/A |
9/30/2014 | 2 | -8 | N/A | -7 | N/A |
6/30/2014 | 2 | -7 | N/A | -6 | N/A |
3/31/2014 | 2 | -8 | N/A | -6 | N/A |
12/31/2013 | 2 | -8 | N/A | -6 | N/A |
9/30/2013 | 4 | -5 | N/A | N/A | N/A |
6/30/2013 | 6 | -2 | N/A | N/A | N/A |
3/31/2013 | 6 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHXM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PHXM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PHXM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PHXM is forecast to have no revenue next year.
High Growth Revenue: PHXM is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PHXM's Return on Equity is forecast to be high in 3 years time